###begin article-title 0
Glutathione S-transferase genotypes modify lung function decline in the general population: SAPALDIA cohort study
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 395 403 <span type="species:ncbi:9606">children</span>
###xml 417 425 <span type="species:ncbi:9606">patients</span>
Understanding the environmental and genetic risk factors of accelerated lung function decline in the general population is a first step in a prevention strategy against the worldwide increasing respiratory pathology of chronic obstructive pulmonary disease (COPD). Deficiency in antioxidative and detoxifying Glutathione S-transferase (GST) gene has been associated with poorer lung function in children, smokers and patients with respiratory diseases. In the present study, we assessed whether low activity variants in GST genes are also associated with accelerated lung function decline in the general adult population.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 82 87 82 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1</italic>
###xml 89 95 89 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 99 105 99 105 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 152 158 152 158 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;75 </sub>
We examined with multiple regression analysis the association of polymorphisms in GSTM1, GSTT1 and GSTP1 genes with annual decline in FEV1, FVC, and FEF25-75 during 11 years of follow-up in 4686 subjects of the prospective SAPALDIA cohort representative of the Swiss general population. Effect modification by smoking, gender, bronchial hyperresponisveness and age was studied.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 57 63 57 63 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;75 </sub>
###xml 123 129 123 129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 183 189 183 189 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 367 373 367 373 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 388 394 388 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 514 520 514 520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 260 263 <span type="species:ncbi:9606">men</span>
###xml 273 278 <span type="species:ncbi:9606">women</span>
###xml 358 361 <span type="species:ncbi:9606">men</span>
###xml 476 479 <span type="species:ncbi:9606">men</span>
###xml 638 641 <span type="species:ncbi:9606">men</span>
The associations of GST genotypes with FEV1, FVC, and FEF25-75 were comparable in direction, but most consistent for FEV1. GSTT1 homozygous gene deletion alone or in combination with GSTM1 homozygous gene deletion was associated with excess decline in FEV1 in men, but not women, irrespective of smoking status. The additional mean annual decline in FEV1 in men with GSTT1 and concurrent GSTM1 gene deletion was -8.3 ml/yr (95% confidence interval: -12.6 to -3.9) relative to men without these gene deletions. The GSTT1 effect on the FEV1 decline comparable to the observed difference in FEV1 decline between never and persistent smoking men. Effect modification by gender was statistically significant.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 33 39 33 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
Our results suggest that genetic GSTT1 deficiency is a prevalent and strong determinant of accelerated lung function decline in the male general population.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 210 211 210 211 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 345 346 345 346 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 494 495 494 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 728 729 728 729 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 759 760 759 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 783 784 783 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
According to estimates by the World Health Organization chronic obstructive pulmonary disease (COPD) has become the fourth most common single cause of death and its prevalence is further increasing world wide [1]. COPD is characterized by irreversible and progressive bronchial obstruction and is associated with persistent airway inflammation [2]. Excess age-related lung function decline is considered a subclinical correlate of COPD and is associated with morbidity and premature mortality [3]. The identification of risk factors leading to accelerated lung function decline is thus needed for efficient COPD prevention. Modifiable risk factors for COPD include active cigarette smoking, occupational dust and fume exposure [4] and possibly air pollution [5] and passive smoking [6].
###end p 11
###begin p 12
###xml 131 140 131 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SERPINA1 </italic>
###xml 146 147 146 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 207 215 207 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SERPINE2</italic>
###xml 255 258 255 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink">ELN</italic>
###xml 361 362 361 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 363 364 363 364 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 690 692 690 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 693 695 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1130 1132 1130 1132 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1133 1135 1133 1135 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1215 1221 1215 1221 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 1225 1230 1225 1230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1</italic>
###xml 1408 1410 1408 1410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 1411 1413 1411 1413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1615 1621 1615 1621 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 1625 1631 1625 1631 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 1650 1656 1650 1656 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 1079 1086 <span type="species:ncbi:4097">tobacco</span>
###xml 1347 1355 <span type="species:ncbi:9606">children</span>
But there is also broad evidence that genetic differences influence the individual's susceptibility to COPD. Rare mutations in the SERPINA1 gene [7], leading to severe alpha 1-antitrypsin deficiency, in the SERPINE2, protease inhibitor 7 gene, and in the ELN, elastin gene, have been identified as genetic predisposing factor in families with early onset COPD [8,9]. To what degree common genetic variants influence susceptibility to COPD in the general population is the focus of intensive research efforts. There is limited evidence from association studies on common genetic polymorphisms in various candidate genes that modify the individual's risk for lung function deficits and COPD [10-13]. But several lines of evidence point to the involvement of the supergene family of glutathione S-transferase (GST) in respiratory disease etiology, including that of COPD. Given their function in the metabolism of environmental toxicants as well as in the inactivation of reactive oxygen species, these genes represent promising candidates for modification of the susceptibility to tobacco-smoke derived and other inhaled irritants [14,15]. Two prevalent homozygous gene deletions of the Mu-1 and Theta-1 GST members (GSTM1 and GSTT1) have repeatedly been associated with increased susceptibility to respiratory disease and lung function deficits in children, asthmatics, and smokers with respiratory symptoms [16-20]. It is, however, unknown whether these GST polymorphisms also influence lung function in the general population. We therefore investigated the association of the three most studied GST polymorphisms (GSTM1 and GSTT1 gene deletions and GSTP1 Ile105Val single nucleotide polymorphism) with change in lung function over an eleven year follow-up using the population-based SAPALDIA cohort (Swiss Cohort Study on Air Pollutants and Lung and Heart Diseases in Adults) and hypothesized that low-activity variants would also accelerate lung function decline in the general adult population.
###end p 12
###begin title 13
Methods
###end title 13
###begin title 14
Study population
###end title 14
###begin p 15
###xml 67 69 67 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 70 72 70 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 85 97 <span type="species:ncbi:9606">participants</span>
###xml 497 509 <span type="species:ncbi:9606">Participants</span>
The SAPALDIA cohort study has been described in details elsewhere [21,22]. In brief, participants predominantly of European-Caucasian ethnicity and Swiss nationality, were randomly selected from eight regional population registries [21,22]. Health examinations at baseline (1991) and follow-up (2002) included an interview about respiratory health, occupational and lifestyle exposures as well as spirometry, a methacholine bronchial challenge test and end-expiratory carbon monoxide measurement. Participants gave informed consent at both surveys separately for health examination, interview and blood analysis. The SAPALDIA cohort study complies with the Helsinki Declaration and has received ethical approval by the central ethics committee of the Swiss Academy of Medical Sciences and the Cantonal Ethics Committees for each of the eight examination areas.
###end p 15
###begin p 16
###xml 593 595 593 595 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25</sub>
###xml 596 599 596 599 <sub xmlns:xlink="http://www.w3.org/1999/xlink">75 </sub>
###xml 1001 1003 1001 1003 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25</sub>
###xml 1004 1006 1004 1006 <sub xmlns:xlink="http://www.w3.org/1999/xlink">75</sub>
###xml 1342 1343 1342 1343 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 62 74 <span type="species:ncbi:9606">participants</span>
###xml 227 239 <span type="species:ncbi:9606">participants</span>
###xml 445 457 <span type="species:ncbi:9606">participants</span>
###xml 657 669 <span type="species:ncbi:9606">participants</span>
###xml 747 759 <span type="species:ncbi:9606">participants</span>
###xml 1084 1096 <span type="species:ncbi:9606">participants</span>
###xml 1173 1185 <span type="species:ncbi:9606">participants</span>
###xml 1482 1494 <span type="species:ncbi:9606">participants</span>
Participation rate in SAPALDIA at baseline was 59.3%. Of 9651 participants examined at baseline, 8047 subjects (86%) agreed to participate fully or partially at follow-up. For the present investigation no selection of SAPALDIA participants was made, but we included all subjects with complete information on outcome and covariate data. 5973 subjects (62%) completed the entire follow-up protocol including spirometry and blood sampling. For 275 participants no DNA was available for genetic testing due to refusal or insufficient blood sample volume. Valid spirometry data on FEV1, FVC and FEF25-75 were not available from both surveys for 215, 310 and 373 participants, respectively. Genotyping for one or more genetic polymorphisms failed in 13 participants. Missing information on one or more covariates included in the regression models further diminished the sample size (n = 784). The final sample size was 4686, 4591 and 4528 subjects for the investigation of annual change in FEV1, FVC and FEF25-75, respectively. Comparison of the baseline characteristics of SAPALDIA cohort participants included in and excluded from this analysis revealed that excluded SAPALDIA participants were on average older, more likely to have been smokers at baseline examination, and had reported a slightly higher number of pack-years at baseline (Table 1). Accordingly lung function was slightly lower and the proportion of subjects with an FEV1/FVC ratio below 70% was slightly higher in non-participants excluded from this current investigation.
###end p 16
###begin p 17
###xml 67 79 <span type="species:ncbi:9606">participants</span>
Baseline characteristics* of the included versus excluded SAPALDIA participants
###end p 17
###begin p 18
* expressed as mean (+/- SD) for quantitative variables and absolute numbers/percentages for categorical variable.
###end p 18
###begin p 19
###xml 16 28 <span type="species:ncbi:9606">participants</span>
dagger SAPALDIA participants at the baseline examination who did not participate at follow-up (n = 3678) [21] or who were excluded from the present analysis due to missing information on outcome or covariate data (n = 1287).
###end p 19
###begin p 20
###xml 62 74 <span type="species:ncbi:9606">Participants</span>
###xml 167 174 <span type="species:ncbi:4097">tobacco</span>
double dagger mean of pack-years among ever smoking subjects. Participants were defined as ever-smokers if they had smoked at least 20 packs of cigarettes or 360 g of tobacco in their life.
###end p 20
###begin p 21
section signFEV1 % predicted calculations based on SAPALDIA specific prediction equations [55, 56].
###end p 21
###begin p 22
###xml 14 15 14 15 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
INSERT [Table 1]
###end p 22
###begin title 23
Spirometry and bronchial hyperresponsiveness
###end title 23
###begin p 24
###xml 99 101 99 101 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 102 104 102 104 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 306 308 306 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 547 548 547 548 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 616 621 616 621 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;75</sub>
###xml 674 676 674 676 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 750 752 750 752 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1 </sub>
###xml 759 765 759 765 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;75 </sub>
###xml 400 411 <span type="species:ncbi:9606">participant</span>
The spirometry measurement procedures at both time points have been described elsewhere in detail [21,22]. Briefly, identical spirometer devices (Sensormedics model 2200, Yorba Linda, USA) and protocols were used at baseline and follow-up and their comparability was assessed prior to the follow-up study [23]. Three to maximal eight forced expiratory lung function manoeuvres were performed by each participant and a minimum of two acceptable forced expiratory flows, forced vital capacity (FVC), forced expiratory volume in the first second (FEV1) and forced expiratory flows during the middle half of the FVC (FEF25-75) complying with American Thoracic Society criteria [24] were obtained. Expiratory flow measures with the highest sum of FVC, FEV1 and FEF25-75 were taken from the same flow-volume curves.
###end p 24
###begin p 25
###xml 74 77 74 75 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
Bronchial hyperresponsiveness (BHR) to methacholine chloride (Provocholine(R), Roche, Nutley, New Jersey, USA) was defined as presence of a 20% or greater drop in FEV1 compared to the highest FEV1-value measured during the test. Increasing concentrations of methacholine (0.39, 1.56, 6.25, and 25.0 mg/ml solutions in a phosphate buffer without phenol) were administered through an aerosol dosimeter (Mefar MB3, Bovezzo, Italy) up to a cumulative dose of 2 mg (8.37 ug/mol).
###end p 25
###begin title 26
Genotyping
###end title 26
###begin p 27
###xml 119 121 110 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 140 146 131 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 150 156 141 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 217 223 208 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 417 420 408 409 <sup xmlns:xlink="http://www.w3.org/1999/xlink">&#174;</sup>
###xml 521 526 510 515 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1</italic>
###xml 618 623 607 612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1</italic>
###xml 676 681 665 670 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1</italic>
###xml 775 780 764 769 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1</italic>
###xml 830 836 819 825 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 1054 1059 1043 1048 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1</italic>
###xml 1060 1066 1049 1055 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 1134 1140 1123 1129 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 1144 1150 1133 1139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 1184 1190 1173 1179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 1291 1297 1280 1286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 1300 1306 1289 1295 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 1519 1525 1508 1514 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 1576 1578 1565 1567 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
DNA was extracted from EDTA blood using the PUREGENEtrade mark DNA purification kit (GENTRA Systems, Minneapolis, USA)[21]. In all subjects GSTM1 and GSTT1 gene deletions and a single nucleotide polymorphism (SNP) in GSTP1 leading to the amino acid substitution Ile105Val were genotyped on the ABI Prism 7000 sequence detection system (Applied Biosystems, Rotkreuz, Switzerland) using 5'nuclease real time PCR (TaqMan(R)) assay and fluorescently labeled allele-specific probes. Following primers and probes were used for GSTM1: forward 5'-GGACATTTTGGAGAACCAGACC-3' and reverse 5'-CTGGATTGTAGCAGATCATGCC-3' primers and GSTM1-specific probe 5'-VIC-TGGACAACCATATGCAG-MGB-3'; for GSTT1: forward 5'-GTCATTCTGAAGGCCAAGGACTT-3' and reverse 5'-GGCATCAGCTTCTGCTTTATGGT-3' primers and GSTT1-specific probe 5'-FAM-CACCTGCAGACCCC-MGB-3'; for GSTP1 Ile105Val: forward 5'-CCTGGTGGACATGGTGAATGAC-3' and reverse 5'-CAGATGCTCACATAGTTGGTGTAGA-3' primers and Ile105 -specific probe 5'-VIC-CTGCAAATACATCTCC-MGB-3'and Val 105 -specific probe 5'-FAM- CTGCAAATACGTCTCC-MGB-3'. GSTM1/GSTT1 assays were repeated for all DNA samples carrying double homozygous GSTM1 and GSTT1 deletions using internal positive GSTP1 controls. All double homozygous deletion carriers could be confirmed. With this approach, hemizygous GSTM1 or GSTT1 carriers were not distinguishable from homozygous carriers. In addition a 5% random sample of all DNA samples was regenotyped with highest reproducibility (>99.5%). Hardy-Weinberg equilibrium (HWE) was tested for GSTP1 Ile105Val using Arlequin (Version 2.000) software [25].
###end p 27
###begin title 28
Statistical analysis
###end title 28
###begin p 29
###xml 2064 2070 2064 2070 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 2074 2080 2074 2080 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 2367 2369 2367 2369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 2835 2844 2835 2844 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a priori </italic>
###xml 2955 2964 2955 2964 <italic xmlns:xlink="http://www.w3.org/1999/xlink">a priori </italic>
###xml 1017 1024 <span type="species:ncbi:4097">tobacco</span>
###xml 1257 1269 <span type="species:ncbi:9606">participants</span>
###xml 1552 1564 <span type="species:ncbi:9606">participants</span>
###xml 2710 2713 <span type="species:ncbi:9606">men</span>
###xml 2735 2740 <span type="species:ncbi:9606">women</span>
###xml 2927 2930 <span type="species:ncbi:9606">men</span>
###xml 2935 2940 <span type="species:ncbi:9606">women</span>
The dependent variable, annual change in lung function, was calculated by dividing the difference between follow-up and baseline lung function by the number of follow-up years. Multiple linear regression analysis was used to estimate in a fixed effect model of the association of GST genotypes with annual change in lung function. Covariates included in the models were baseline lung function, age, sex, height, weight change during follow-up, study center, level of education, exposure to gas and dust at work at baseline, smoking status at baseline and at follow-up, pack-years smoked at baseline and during follow-up. Cumulative cigarette smoking exposure was summarized in two separate variables: "pack-years smoked up to baseline" and "pack-years smoked during follow-up". The following categories of smoking status were derived for the current study: "Never smokers" reported to be non-smokers at both surveys (n = 2258). "Ever smokers" had to have smoked more than 20 packs of cigarettes or more than 360 g of tobacco (n = 2428) in their lifetime by the end of the follow-up period. Ever smokers were further divided into: "persistent smokers" reported current smoking at both surveys (n = 1026), and "others" were all remaining subjects, comprising participants reporting at both surveys former smoking (n = 944), quitting smoking during follow-up (n = 387), starting smoking during follow-up (n = 38), non-smoking at baseline and former smoking at follow-up (n = 29) and former smoking at baseline and current smoking at follow-up (n = 4). 48 participants provided inconsistent smoking information. Exclusion of these subjects in a sensitivity analysis did not change the strength or the direction of the association observed. Effect modification of genotype/lung function associations by gender, smoking status, and smoking intensity (pack-years up to baseline and during follow-up in ever smokers), as well as BHR and age, was assessed by including according multiplicative interaction terms in the regression models. Trend tests for the combination of GSTT1 and GSTM1 genotypes were conducted by using a genotype combination variable coded as "presence of zero, one and two gene deletion polymorphisms" as ordinal variable in the model. Two-sided p-values of <0.05 and <0.10 were considered as statistically significant for main effects and interactions [26], respectively. Correction for multiple testing was done using the conservative Bonferroni correction. The associations were corrected for the number of statistical tests performed (main effects and interactions with gender and smoking intensity) (thirty comparisons per lung function parameter investigated, consisting of fifteen tests in men and fifteen tests in women: all; never smokers; persistent smokers). The Bonferroni corrected significance level for the a priori hypotheses regarding association between GST genotypes and lung function change in men and women including the a priori assessment of interaction with gender and smoking and was P > 0.0017. Sensitivity analyses regarding age and BHR were not corrected for multiple testing. All analyses were conducted using STATA SE version 8.0 (Stata Corporation, TX, USA).
###end p 29
###begin title 30
Results
###end title 30
###begin p 31
###xml 64 65 64 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 791 793 787 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 794 796 790 792 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 797 799 793 795 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 802 808 798 804 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 812 818 808 814 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 893 899 889 895 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 91 96 <span type="species:ncbi:9606">women</span>
###xml 110 113 <span type="species:ncbi:9606">men</span>
###xml 197 209 <span type="species:ncbi:9606">participants</span>
###xml 441 444 <span type="species:ncbi:9606">men</span>
###xml 475 480 <span type="species:ncbi:9606">women</span>
###xml 496 501 <span type="species:ncbi:9606">Women</span>
###xml 564 567 <span type="species:ncbi:9606">men</span>
###xml 604 609 <span type="species:ncbi:9606">women</span>
Characteristics of the study population are summarized in Table 2. The study included more women (52.4%) than men (47.6%). Reflecting recruitment as a random sample of the Swiss general population participants had on average good lung function at baseline and follow-up. FEV1 percent predicted at baseline and follow-up was 100.2% and 97.0% of predicted values, respectively. The mean annual change in FEV1 was -39.6 ml/yr (SD: +/- 33.6) in men and -31.8 ml/yr (+/- 26.2) in women, respectively. Women were more likely to be never smokers. Among smoking subjects, men smoked on average more heavily than women (21.8 pack-years vs. 14.5 pack-years at baseline; 7.1 vs. 5.5 pack-years during follow-up). The observed GST genotype distributions agreed well with previous reports in Caucasians [19,27,28]. GSTM1 and GSTT1 null genotypes were present in 53% and 18% of all subjects. The homozygous GSTP1 Val/Val genotype was present in 9.4% and its allele distribution was in Hardy-Weinberg equilibrium.
###end p 31
###begin p 32
###xml 14 15 14 15 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
INSERT [Table 2]
###end p 32
###begin p 33
Characteristics* of the study population, the SAPALDIA Cohort
###end p 33
###begin p 34
* expressed as mean (+/- SD) for quantitative variables and absolute numbers/percentages for categorical variable.
###end p 34
###begin p 35
###xml 143 155 <span type="species:ncbi:9606">participants</span>
dagger "Never" smokers reported non-smoking at both surveys. "Persistent" smokers reported current smoking at both surveys. "Others" comprised participants reporting at both surveys former smoking (n = 944), quitting smoking during follow-up (n = 387), starting smoking during follow-up (n = 38), non-smoking at baseline and former smoking at follow-up (n = 29) and former smoking at baseline and current smoking at follow-up (n = 4).
###end p 35
###begin p 36
double dagger mean of pack-years among ever smoking subjects. Ever-smokers encompass both, persistent smokers and others.
###end p 36
###begin p 37
section signFEV1 % predicted calculations based on predicted values from SAPALDIA specific prediction equations [55, 56].
###end p 37
###begin title 38
Association of GST genotypes with lung function decline
###end title 38
###begin p 39
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 39 45 39 45 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 133 139 133 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 182 188 182 188 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 297 303 297 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 390 396 390 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 418 424 418 424 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;75 </sub>
###xml 560 566 560 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 570 576 570 576 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 680 686 680 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 694 700 694 700 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 824 829 824 829 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;75</sub>
###xml 867 873 867 873 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 911 917 911 917 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 970 976 970 976 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;75 </sub>
###xml 989 994 989 994 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1</italic>
###xml 995 1001 995 1001 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 254 257 <span type="species:ncbi:9606">men</span>
###xml 267 272 <span type="species:ncbi:9606">women</span>
###xml 274 277 <span type="species:ncbi:9606">Men</span>
###xml 507 510 <span type="species:ncbi:9606">Men</span>
###xml 640 643 <span type="species:ncbi:9606">men</span>
No independent association of GSTM1 or GSTP1 genotype with any of the lung function parameters was observed, irrespective of gender. GSTT1 gene deletion alone or in combination with GSTM1 deletion was associated with accelerated lung function decline in men, but not women. Men homozygous for the GSTT1 gene deletion exhibited an excess annual change in FEV1 of -5.3 ml/yr (P = 0.001). The GSTT1 effects on FVC and FEF25-75 were comparable in size and direction, but did not reach statistical significance. Men carrying the double homozygous gene deletions of GSTT1 and GSTM1 had on average a -8.3 ml/yr greater annual decline in FEV1 than men with at least one copy of both, the GSTT1 and the GSTM1 gene (P for trend <0.001); the according excess change was -6.5 ml/yr (P = 0.045) for FVC and -7.8 ml/yr (P = 0.094) for FEF25-75. The interactions between gender and GSTT1 deletion alone or in combination with GSTM1 deletion were statistically significant for FEV1, FEF25-75 and FVC (for GSTT1/GSTM1 combination only).
###end p 39
###begin p 40
###xml 14 15 14 15 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
INSERT [Table 3]
###end p 40
###begin p 41
###xml 93 99 88 94 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;75 </sub>
Adjusted* associations of GST genotypesdagger with excess annual decline in FEV1, FVC and FEF25-75 stratified by sex, the SAPALDIA Cohort.
###end p 41
###begin p 42
* The effects of GST genotypes are adjusted for the respective baseline lung function parameter, smoking status at baseline and follow-up, pack-years smoked at baseline and during follow-up, height, weight change between surveys, study area, gas and dust exposure at baseline and education level.
###end p 42
###begin p 43
###xml 7 13 2 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 17 23 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 145 151 140 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 295 301 290 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 302 308 297 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
dagger GSTM1 and GSTT1 genotypes were dichotomized into absence vs. presence of homozygous gene deletions (non-null vs. null). The effect of the GSTP1 genotype on lung function change was investigated in a co-dominant genetic model with the Ile/Ile genotype as the reference group. The combined GSTM1 /GSTT1 genotype (GSTM1T1) was coded as "presence of zero, one and two homozygous gene deletion polymorphisms" and included as ordinal variable in the linear regression model.
###end p 43
###begin p 44
double dagger Change in lung function parameter represented the difference between lung function parameter measured at follow-up [ml] and the one measured at baseline [ml] divided by the duration of follow-up period [yr]. Coefficient values below zero correspond to an excess decline in lung function [ml/yr] compared to the decline in the reference group and coefficient values above zero correspond to a less steep decline in lung function compared of the reference group.
###end p 44
###begin p 45
section signUncorrected P-values for differences between categories. Bonferroni corrected significance level for multiple comparisons: P < 0.0017.
###end p 45
###begin p 46
paragraph signStatisically significant (uncorrected P-value > 0.05). ** Statistically significant after Bonferoni-correction (P-value > 0.0017)
###end p 46
###begin p 47
daggerdagger Interaction between genotype and gender was assessed by including interaction terms in the model.
###end p 47
###begin p 48
###xml 118 124 118 124 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 162 168 162 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 303 309 303 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 313 319 313 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
The majority of the reported association results did not withhold the conservative Bonferroni correction; however the GSTT1 genotype alone or in combination with GSTM1 genotype showed a significant association with annual change in FEV1 even after Bonferroni correction. The effect of double homozygous GSTT1 and GSTM1 deletion on lung function decline is graphically presented as predicted mean annual FEV1 decline in different genotype/gender strata.
###end p 48
###begin p 49
###xml 15 16 15 16 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1</xref>
INSERT [Figure 1]
###end p 49
###begin p 50
###xml 73 79 73 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 83 89 83 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
Predicted* mean annual change in lung function parameter by the combined GSTT1 and GSTM1 gene deletion genotype and sex, the SAPALDIA cohort.
###end p 50
###begin p 51
###xml 41 46 41 46 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;75</sub>
* adjusted for baseline FEV1, FVC and FEF25-75, respectively, as well as for smoking status at baseline and follow-up, pack-years smoked at baseline and during follow-up, height, weight change between surveys, study area, gas and dust exposure at baseline and education level.
###end p 51
###begin p 52
dagger P-values for difference with reference group GSTM1T1 both non-null.
###end p 52
###begin title 53
Effect modification by smoking
###end title 53
###begin p 54
###xml 787 793 783 789 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 796 802 792 798 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 863 869 859 865 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;75 </sub>
###xml 913 919 909 915 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 1054 1060 1050 1056 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 1093 1099 1089 1095 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 1174 1180 1170 1176 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 1288 1294 1284 1290 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 1602 1607 1598 1603 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;75</sub>
###xml 1613 1619 1609 1615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 1657 1663 1653 1659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 1817 1823 1813 1819 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 1966 1972 1962 1968 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;75 </sub>
###xml 209 212 <span type="species:ncbi:9606">men</span>
###xml 1727 1732 <span type="species:ncbi:9606">women</span>
An important determinant of premature lung function decline is active smoking. In our study population, persistent male smokers exhibited on average an -6.6 ml/yr greater annual FEV1 change than never smoking men; the average change in FEV1 was -42.8 ml/yr (+/- 35.6) in male persistent smokers and -36.2 ml/yr (+/- 33.2) in male never smokers. In persistent smokers each pack-year smoked during follow-up was associated with an excess average annual FEV1 change of -0.8 ml/yr. We assessed the impact of genetic GST deficiency on lung function decline separately for never smokers and persistent smokers; associations observed in ever-smokers were similar to those reported here for persistent smokers (data not shown). Irrespective of gender or smoking status no independent effects of GSTM1 or GSTP1 Ile105Val genotype on accelerated decline of FEV1, FVC or FEF25-75 were observed. Male persistent smokers with GSTT1 null genotype exhibited on average an excess annual decline in FEV1 of -8.0 ml/yr (P = 0.013) when compared to persistent smokers with GSTT1 non-null genotype. The according GSTT1 effect in male never smokers was -5.6 ml/yr (P = 0.025). The difference in GSTT1 effect between persistent and never smokers was not statistically significant (P for interaction>0.10). The GSTT1 effect in persistent smokers was modified by packyears smoked to baseline (P for interaction<0.001) and during follow-up (P for interaction = 0.029). Similar trends for the GSTT1 effect on FEV1 decline in smoking strata, though lacking statistical significance, were observed for FVC and less clearly for FEF25-75. The GSTT1 genotype alone or in combination with GSTM1 genotype was not associated with excess lung function change in women, irrespective of smoking status. There was a suggestion that heterozygosity for the GSTP1 Ile105Val SNP was associated with slower decline in FVC in persistent smokers (P = 0.030), but no according heterozygous effects on FEV1 or FEF25-75 were observed.
###end p 54
###begin p 55
###xml 14 15 14 15 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
INSERT [Table 4]
###end p 55
###begin p 56
###xml 93 99 88 94 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;75 </sub>
Adjusted* associations of GST genotypesdagger with excess annual decline in FEV1, FVC and FEF25-75 stratified by smoking status and sex, the SAPALDIA Cohort.
###end p 56
###begin p 57
* The effects of GST genotypes are adjusted for the respective baseline lung function parameter, smoking status at baseline and follow-up, pack-years smoked at baseline and during follow-up, height, weight change between surveys, study area, gas and dust exposure at baseline and education level.
###end p 57
###begin p 58
###xml 7 13 2 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 17 23 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 145 151 140 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 295 301 290 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 302 308 297 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
dagger GSTM1 and GSTT1 genotypes were dichotomized into absence vs. presence of homozygous gene deletions (non-null vs. null). The effect of the GSTP1 genotype on lung function change was investigated in a co-dominant genetic model with the Ile/Ile genotype as the reference group. The combined GSTM1 /GSTT1 genotype (GSTM1T1) was coded as "presence of zero, one and two homozygous gene deletion polymorphisms" and included as ordinal variable in the linear regression model.
###end p 58
###begin p 59
double dagger Change in lung function parameter represented the difference between lung function parameter measured at follow-up [ml] and the one measured at baseline [ml] divided by the duration of follow-up period [yr]. Coefficient values below zero correspond to an excess decline in lung function [ml/yr] compared to the decline in the reference group and coefficient values above zero correspond to a less steep decline in lung function compared of the reference group.
###end p 59
###begin p 60
section signUncorrected P-values for differences between categories. Bonferroni corrected significance level for multiple comparisons: P < 0.0017.
###end p 60
###begin p 61
ll Interaction between pack-years and genotype in smokers was assessed by including interaction terms in the models. Cumulative cigarette smoking exposure was summarized in two separate variables: "pack-years smoked up to baseline" and "pack-years smoked during follow-up".
###end p 61
###begin p 62
paragraph signStatisically significant (uncorrected P-value > 0.05).
###end p 62
###begin title 63
Sensitivity analysis: modification of the GST effects by BHR
###end title 63
###begin p 64
###xml 71 73 71 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 231 232 231 232 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 372 373 372 373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
The GST genotypes have previously been associated with asthma and BHR [28]. Restriction of the analysis to subjects without a report of asthma (data not shown) and without the presence of BHR at either baseline or follow-up (Table 5) revealed comparable associations in size between GST genotypes and lung function change as reported for the whole study population (Table 3), irrespective of gender and lung function parameter. Thus the observed GST/lung function decline associations are not merely due to an effect of GST on asthma or BHR.
###end p 64
###begin p 65
###xml 93 99 88 94 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;75 </sub>
###xml 102 105 <span type="species:ncbi:9606">men</span>
###xml 110 115 <span type="species:ncbi:9606">women</span>
Adjusted* associations of GST genotypesdagger with excess annual decline in FEV1, FVC and FEF25-75 in men and women, stratified by absence or presence of BHR at baseline or follow-up, the SAPALDIA Cohort.
###end p 65
###begin p 66
* The effects of GST genotypes are adjusted for the respective baseline lung function parameter, smoking status at baseline and follow-up, pack-years smoked at baseline and during follow-up, height, weight change between surveys, study area, gas and dust exposure at baseline and education level.
###end p 66
###begin p 67
###xml 7 13 2 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 17 23 12 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 145 151 140 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 295 301 290 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 302 308 297 303 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
dagger GSTM1 and GSTT1 genotypes were dichotomized into absence vs. presence of homozygous gene deletions (non-null vs. null). The effect of the GSTP1 genotype on lung function change was investigated in a co-dominant genetic model with the Ile/Ile genotype as the reference group. The combined GSTM1 /GSTT1 genotype (GSTM1T1) was coded as "presence of zero, one and two homozygous gene deletion polymorphisms" and included as ordinal variable in the linear regression model.
###end p 67
###begin p 68
double dagger Change in lung function parameter represented the difference between lung function parameter measured at follow-up [ml] and the one measured at baseline [ml] divided by the duration of follow-up period [yr]. Coefficient values below zero correspond to an excess decline in lung function [ml/yr] compared to the decline in the reference group and coefficient values above zero correspond to a less steep decline in lung function compared of the reference group.
###end p 68
###begin p 69
section signUncorrected P-values for differences between categories.
###end p 69
###begin p 70
paragraph signStatistically significant (uncorrected P-value > 0.05).
###end p 70
###begin p 71
daggerdagger Interaction between genotype and BHR was assessed by including interaction terms in the model.
###end p 71
###begin p 72
###xml 51 53 51 53 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 167 168 167 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 210 216 210 216 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 220 226 220 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 391 397 391 397 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 409 415 409 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 505 511 505 511 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;75 </sub>
###xml 601 613 601 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1/GSTT1 </italic>
###xml 684 690 684 690 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;75 </sub>
###xml 897 902 <span type="species:ncbi:9606">women</span>
BHR was previously shown to be predictive of COPD [29]. Results of the investigation of the GST effects on decline in lung function among BHR positive subjects (Table 5) suggested that the respective impact of GSTT1 and GSTM1 gene deletion might be modified by BHR. The interaction between GST genotypes and BHR did not reach statistical significance, though. In male BHR positive subjects, GSTM1 rather then GSTT1 deficiency was associated with accelerated decline in FEV1 (-8.2 ml/yr, P = 0.017) and FEF25-75 (-12.4 ml/yr, P = 0.051). Again, the lung function decline was strongest for the combined GSTM1/GSTT1 genotypes, consistent with a gene dose-response. For both, FEV1 and FEF25-75 effect estimates for GSTM1T1 both null were stronger than those observed among male BHR negative subjects. No association of GST genotype with FVC was observed in male BHR positive subjects. In BHR positive women again no statistically significant GST genotype/lung function associations were observed.
###end p 72
###begin p 73
###xml 14 15 14 15 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
INSERT [Table 5]
###end p 73
###begin title 74
Sensitivity analysis: GST effect in age restricted subpopulation
###end title 74
###begin p 75
###xml 443 445 443 445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 504 510 504 510 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 539 545 539 545 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 653 659 653 659 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 697 703 697 703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 707 713 707 713 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 818 823 818 823 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1</italic>
###xml 852 858 852 858 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 862 868 862 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 962 968 962 968 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 994 1000 994 1000 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;75 </sub>
###xml 1057 1062 1057 1062 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1</italic>
###xml 1091 1097 1091 1097 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 1101 1107 1101 1107 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 1175 1181 1175 1181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 1226 1232 1226 1232 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;75 </sub>
###xml 1270 1275 1270 1275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1</italic>
###xml 472 475 <span type="species:ncbi:9606">men</span>
###xml 1025 1028 <span type="species:ncbi:9606">men</span>
###xml 1305 1310 <span type="species:ncbi:9606">women</span>
Both, lung function growth and decline are age-dependent processes. The SAPALDIA cohort also includes young adults (age at baseline 18 to 60 years). To confirm that the observed associations between GST genotype and lung function change are due to an impact of these genotypes on age-related decline, we restricted analysis to subjects older than 30 years, an age at which lung growth has ceased and age-related lung function decline started [30] (data not presented). In men we observed associations of GSTT1 alone or in combination with GSTM1 with change in FEV1 and FVC that were similar in trend to the ones observed in the entire study sample (for GSTT1 and FEV1: -5.8 ml/yr (P = 0.001); for GSTM1 and GSTT1 both null and FEV1: -7.4 ml/yr (P = 0.009)). The association with change in FVC was more pronounced (for GSTT1: -4.4 ml/yr (P = 0.08); for GSTM1 and GSTT1 both null: -9.5 ml/yr (P = 0.005)). In contrast, the non-significant association observed for GSTT1 genotype and change in FEF25-75 was no longer present in men aged 30 years or older (for GSTT1: -0.4 ml/yr (P = 0.89); for GSTM1 and GSTT1 both null: -1.9 ml/yr (P = 0.72)). Instead, the association between GSTM1 null genotype and excess annual change in FEF25-75 became statistically significant (for GSTM1: -7.6 ml/yr (P = 0.024)). In women over age 30 at baseline, we did not observe any GST genotype/lung function decline association.
###end p 75
###begin title 76
Discussion
###end title 76
###begin p 77
###xml 33 39 33 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 79 85 79 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 259 265 259 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 184 187 <span type="species:ncbi:9606">men</span>
###xml 197 202 <span type="species:ncbi:9606">women</span>
Our results suggest that genetic GSTT1 deficiency alone or in combination with GSTM1 deficiency is independently associated with an accelerated age-related decline of lung function in men, but not women, irrespective of smoking status. The impact size of the GSTT1 genotype was comparable to the difference in FEV1 decline that we observed between male persistent smokers and never smokers.
###end p 77
###begin p 78
###xml 394 396 394 396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 397 399 397 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 634 636 634 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 953 955 953 955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 956 958 956 958 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1340 1342 1340 1342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 279 287 <span type="species:ncbi:9606">children</span>
###xml 501 508 <span type="species:ncbi:4097">tobacco</span>
This is the first study reporting an association between GST genotypes and lung function in the general adult population. Genetically determined GST deficiency has previously been associated with deficits in lung function growth and respiratory symptoms in healthy and asthmatic children exposed to oxidative inhalants such as high ambient ozone concentrations and passive smoke, respectively [20,31]. While GSTs are well known for their role in the metabolism of exogenous toxic substrates including tobacco derived substances, they also exhibit peroxidase activity and thus might play an important role in oxidative stress defense [15]. The fundamental relevance of the oxidative stress pathway to respiratory health and disease is evidenced by the fact that dietary and circulating antioxidants have been suggested by a number of epidemiological studies to protect the lung from accelerated pulmonary function decline and other respiratory diseases [32-34]. The current observation that the GST genotype effects were even present in never smokers living in study areas with moderate concentrations of ambient ozone and other air pollutants is in line with this notion and with experimental data suggesting that various air pollutants as well as chronic inflammatory processes can cause oxidative damage to the lung tissue at low levels [35].
###end p 78
###begin p 79
###xml 4 10 4 10 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 97 103 97 103 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;75 </sub>
###xml 295 301 295 301 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 329 335 329 335 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;75 </sub>
###xml 417 423 417 423 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;75 </sub>
###xml 544 550 544 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 580 586 580 586 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 682 688 682 688 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 882 884 882 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 948 954 948 954 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;75 </sub>
###xml 1006 1008 1006 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 1044 1046 1044 1046 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 1057 1059 1057 1059 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1116 1122 1116 1122 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;75 </sub>
###xml 1373 1379 1373 1379 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;75 </sub>
###xml 1386 1391 1386 1391 <sub xmlns:xlink="http://www.w3.org/1999/xlink">25&#8211;75</sub>
###xml 1746 1748 1746 1748 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 1217 1229 <span type="species:ncbi:9606">participants</span>
The GSTT1 effect was most consistent for FEV1 and overall comparable in direction for FVC and FEF25-75 in our study. Yet our results suggest that the respective impacts of GST genotypes on the different lung function parameters may depend on the smoking status, BHR and age. The strength of the GSTT1 association with FVC and FEF25-75 differed between never smokers and persistent smokers. The effect on change in FEF25-75 was not observed in persistent smokers as also reflected by the lack of interaction of smoking history (pack-years) with GSTT1 genotype, suggesting that the GSTT1 affects predominately large airway caliber in smokers. In addition no statistically significant GSTT1 effect on any lung function parameter was observed in subjects with bronchial hyperresponsiveness. Accelerated decline in FEV1 has been well characterized to correlate with development of COPD [36], but measures of small airways function such as changes in FEF25-75 have also been reported to be of relevance in COPD [37]. Air pollutant exposure to ozone [38] and NO2 [39] has often been associated with a greater decline in FEF25-75 than in FEV1. Differences in age, as well as differences in genotypes investigated between our participants and previous study populations may explain in part the inconsistency in the GST effects on various lung function parameters. Alterations in FEF25-75 and FEF25-75/FVC have been interpreted as indicators of airway-parenchymal dysanaptic lung growth. These parameters may be of greater relevance as an outcome for GST and oxidant effects during childhood. Ongoing research into genetic determinants of various lung function parameters may provide further insight into the biology of different lung function parameters [40].
###end p 79
###begin p 80
###xml 465 467 465 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 672 674 672 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 675 677 675 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 782 784 782 784 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 857 859 857 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 1141 1143 1141 1143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B47">47</xref>
###xml 1273 1275 1273 1275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B48">48</xref>
###xml 1321 1323 1321 1323 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 1371 1373 1371 1373 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 1374 1376 1374 1376 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 1544 1546 1544 1546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1700 1706 1700 1706 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 1707 1709 1707 1709 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 483 486 <span type="species:ncbi:9606">men</span>
###xml 491 496 <span type="species:ncbi:9606">women</span>
###xml 599 604 <span type="species:ncbi:9606">women</span>
###xml 625 628 <span type="species:ncbi:9606">men</span>
###xml 657 664 <span type="species:ncbi:4097">tobacco</span>
###xml 721 726 <span type="species:ncbi:9606">women</span>
###xml 920 925 <span type="species:ncbi:9606">women</span>
###xml 975 978 <span type="species:ncbi:9606">men</span>
###xml 1122 1125 <span type="species:ncbi:9606">men</span>
###xml 1134 1139 <span type="species:ncbi:9606">women</span>
###xml 1146 1151 <span type="species:ncbi:9606">Women</span>
###xml 1164 1167 <span type="species:ncbi:9606">men</span>
###xml 1392 1397 <span type="species:ncbi:9606">women</span>
###xml 1457 1460 <span type="species:ncbi:9606">men</span>
A novel finding of our population-based study is the pronounced gender difference in the association between GST genotypes and age-related change in lung function. Though the biological basis of these observed gender differences is unknown, gender differences in lung function and respiratory diseases have consistently been observed throughout life. They can be attributed in part to sex-specific immunological and hormonal patterns associated with lung function [41]. In addition, men and women seem to differ in susceptibility to exogenous exposures. On one hand comparative studies suggest that women recover better than men from the adverse effects of tobacco smoke [42-44]. On the other hand there is evidence that women had greater respiratory deficits per pack-year smoked [45] as well as higher DNA adducts levels when adjusted for cigarette dose [46]. Several other lines of evidence indicate in contrast that women might be more resistant to oxidative stress than men. In smokers, air flow obstruction was reported to be more strongly associated with the presence of high-grade preinvasive epithelial lesion in men than in women [47]. Women compared to men were found to exhibit increased systemic antioxidant capacities such as higher glutathione blood levels [48], increased glutathione peroxidase activity [49] and less oxidant-damaged DNA at advanced age [50,51]. In addition, women often report increased antioxidant intake when compared to men, which may make them less receptive for an effect of low penetrance gene variants [34]. Finally, recently reported evidence suggests that the estrogen receptor is involved in the up-regulation of oxidative stress defensive genes including GSTP1 [52] supporting the notion that sex-specific mechanisms in the defense response to oxidative stress exist. If confirmed by additional studies, our results which point to a sex-specific GST impact on lung function might be indicative of a broad biological basis for gender difference in susceptibility to airborne toxicants.
###end p 80
###begin p 81
###xml 310 312 310 312 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 313 315 313 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 316 318 316 318 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 319 321 319 321 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 322 324 322 324 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 331 337 331 337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 460 462 460 462 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 463 465 463 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 552 558 552 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 592 594 592 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 595 597 595 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 683 689 683 689 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 771 777 771 777 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 1003 1005 1003 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 1006 1008 1006 1008 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 1203 1205 1203 1205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 1260 1266 1260 1266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 1277 1283 1277 1283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 1312 1318 1312 1318 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 1379 1385 1379 1385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 1512 1514 1512 1514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1886 1892 1886 1892 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 1895 1901 1895 1901 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 2094 2096 2094 2096 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 2223 2229 2223 2229 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 639 644 <span type="species:ncbi:9606">women</span>
###xml 975 987 <span type="species:ncbi:9606">participants</span>
###xml 1138 1146 <span type="species:ncbi:9606">children</span>
###xml 1246 1254 <span type="species:ncbi:9606">children</span>
We observed in the male SAPALDIA population differences in the relative impact of specific GST polymorphisms on lung function. In fact, results from previous studies suggest that the respective relevance of GST genes on respiratory health may depend on age, health and exposure status of the study population [16,18,19,53,54]. The GSTT1 gene deletion polymorphism has previously been identified as an important determinant of age-related lung function change [19,53]. In the Lung Health Study (LHS) the rate of lung function decline was accelerated in GSTT1 deficient smokers with mild COPD [19,53]. No gender difference was observed, but women were underrepresented in the LHS. The GSTT1 effect was stronger in mild as opposed to heavy smokers, whereas in our study the GSTT1 effect was more pronounced in smokers and with increasing pack-years. This discrepancy to the LHS results might be attributable to the comparatively better respiratory health state of the SAPALADIA participants (FEV1 % pred. [55,56] at follow-up: 97%) and to their more moderate smoking habits. The relative impact of specific GST genotypes on lung function in children may be different from that in adults. Gilliland et al. [20] reported lower lung function growth in children with GSTP1 105Val and GSTM1 null genotypes, but not with GSTT1 null genotype. In agreement with our results, no independent GSTM1 effect on pulmonary function was observed in healthy, non-smoking freshmen students, irrespective of their antioxidant intake [34]. Exclusion of younger age groups in our study population did not modify the reported associations, demonstrating that the findings on association between GST genotypes and lung function change were mostly due to the genotype impact on age related lung function decline rather than on lung function growth. As suggested by our sensitivity analysis the relative impact of GSTT1 or GSTM1 gene deletion may also depend on the presence or absence of BHR. There is evidence that BHR responsive airways are more vulnerable to oxidative particles and to airway inflammation in general [57]. This altered physiology of the BHR positive lung tissue might provide a pathophysiologic basis for the respective impact of GSTM1 deficiency reported here.
###end p 81
###begin p 82
###xml 49 55 49 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 79 85 79 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 150 152 150 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 172 178 172 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 351 353 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 379 385 379 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 389 395 389 395 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 413 419 413 419 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 494 496 494 496 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 521 527 521 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 588 590 588 590 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 591 593 591 593 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 594 596 594 596 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 680 686 680 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 778 780 778 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 783 788 783 788 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1</italic>
###xml 863 865 863 865 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 918 924 918 924 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 1052 1054 1052 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 1074 1080 1074 1080 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 1162 1164 1162 1164 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 1165 1167 1165 1167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 1260 1266 1260 1266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 1319 1325 1319 1325 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
Results are most inconsistent with regard to the GSTP1 Ile105Val genotype. The GSTP1 105Val allele was found to be protective against asthma and BHR [54]. In the LHS study GSTP1 105Val/Val genotype was associated with lower lung function at baseline as well as with more rapid lung function decline in smokers with high baseline lung function values [19]. Yet the combination of GSTM1 and GSTT1 gene deletion and GSTP1 105Ile/Ile was defined as risk genotype in the follow-up study of the LHS [53]. In other studies, the GSTP1 105Ile/Ile genotype was inconsistently associated with COPD [13,54,58]. In vitro assays further underline the complexity of the functional impact of the GSTP1 Ile105Val polymorphism, since the relative activity of the variants is substrate dependent [59]. GSTP1, the most abundantly expressed member of the GST gene family in the lung [60], may have a complex impact on respiratory disease. GSTP1 appears to act not only as a detoxifying and antioxidative enzyme, but also as direct inhibitor of the C-Jun N terminal kinase [61]. Accordingly, low GSTP1 expression or activity has been reported to promote apoptosis in lung epithelium [54,62]. Future studies investigating more comprehensively genetic variation and haplotypes of the GSTP1 gene should improve our understanding of the role of GSTP1 at various developmental and phenotypic levels of respiratory health.
###end p 82
###begin p 83
###xml 1395 1401 1395 1401 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTP1 </italic>
###xml 1639 1645 1639 1645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 1649 1655 1649 1655 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 1910 1912 1910 1912 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 2027 2029 2027 2029 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 2317 2319 2317 2319 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 2503 2509 2503 2509 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 2512 2518 2512 2518 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 2687 2693 2687 2693 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 2697 2703 2697 2703 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTM1 </italic>
###xml 135 147 <span type="species:ncbi:9606">participants</span>
###xml 451 463 <span type="species:ncbi:9606">participants</span>
###xml 593 605 <span type="species:ncbi:9606">participants</span>
###xml 658 670 <span type="species:ncbi:9606">participants</span>
###xml 1105 1117 <span type="species:ncbi:9606">participants</span>
The strength of the SAPALDIA cohort is its prospective design, its large sample size as well as the detailed characterization of study participants. However, several limitations of the study deserve to be discussed. First, the study cohort was evaluated at two single time points eleven years apart and the range of factors influencing lung function decline were assessed through personal interviews depending on reporting/recalling bias of the study participants. Also there is the concern for selection bias for participation at follow-up. Comparison of baseline characteristics of SAPALDIA participants included in this investigation with SAPALDIA cohort participants not included in this analysis due to missing covariate information suggested that the population sample investigated here represents a younger, and less actively smoking and healthier sample. GST genotypes were not associated with age or smoking behavior among subjects included in this study. Since it is not likely that GST genotypes influenced study participation, non-participation at baseline, loss to follow-up and exclusion of participants due to lacking covariate information is unlikely to invalidate the results presented. Second, a hypothetical limitation of our association study may be potential population stratification since the Swiss population consists of multiple language groups. Deviation of HWE of the GSTP1 Ile105Val genotype was not observed within the three language groups presented in our study (French, German and Italian); the genotype distribution was comparable in the three language groups. The prevalence of gene deletion genotypes of GSTM1 and GSTT1 and were not statistically significantly different by language region or nationality. Neither language group nor Swiss nationality did modify the observed associations between GST deficient genotypes and lung function decline. Given the low power of HWE [63], genotype data from additional unlinked genetic markers should ideally be used for testing population admixture [64]. However limited funding prohibited this control of population stratification in our study. Nevertheless we do not expect population stratification in this Swiss cohort to invalidate the observed associations since genetic homogeneity of Caucasian Western-Central European populations [65] has been repeatedly described. A further limitation of the study is the fact that the genetic analysis chosen does not permit to disentangle heterozygotes from homozygotes wild type GSTT1 or GSTM1 genotypes. It is conceivable that even stronger associations with lung function could have been observed in a contrast of subjects without any deletion allele versus no GSTT1 and GSTM1 gene. Finally sample size was limited for the assessment of GST genotype effects among BHR positive subjects.
###end p 83
###begin p 84
###xml 236 242 236 242 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1 </italic>
###xml 298 310 298 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">GSTT1/GSTM1 </italic>
In conclusion our results suggest that common genetic polymorphisms can influence the rate of lung function decline in the general population. A large proportion of the Caucasian population carry one or both GST gene deletions (~20% of GSTT1 gene deletion, ~50% the GSTM1 gene deletion and ~10% of GSTT1/GSTM1 gene deletion carriers). The high prevalence and the strong effect size, which is comparable to the effect of smoking, underscore the public health relevance of our results. Additional studies need to confirm and identify the biological mechanisms underlying the newly observed gender difference in GST genotype effects on age-related lung function decline.
###end p 84
###begin title 85
Abbreviations
###end title 85
###begin p 86
BHR - Bronchial hyperresponsiveness
###end p 86
###begin p 87
BMI - Body Mass Index
###end p 87
###begin p 88
COPD - chronic obstructive pulmonary disease
###end p 88
###begin p 89
DNA - desoxyribonucleic acid
###end p 89
###begin p 90
EDTA - ethylenediaminetetraacetic acid
###end p 90
###begin p 91
FEV1 - forced expiratory volume in one second
###end p 91
###begin p 92
FVC - forced vital capacity
###end p 92
###begin p 93
GST - Glutathione S-transferase
###end p 93
###begin p 94
HWE - Hardy-Weinberg equilibrium
###end p 94
###begin p 95
Ile - isoleucine
###end p 95
###begin p 96
LHS - Lung Health Study
###end p 96
###begin p 97
PCR - polymerase chain reaction
###end p 97
###begin p 98
SAPALDIA - Study on Air Pollution And Lung Disease In Adults
###end p 98
###begin p 99
Val - valine
###end p 99
###begin title 100
Competing interests
###end title 100
###begin p 101
The author(s) declare that they have no competing interests.
###end p 101
###begin title 102
Authors' contributions
###end title 102
###begin p 103
NMPH conceived the specific research question and designed the SAPALDIA biological sample collection. MI and NMPH established the SAPALDIA DNA bank. OS, MI performed genotype analysis. GM, WB gave major infrastructure support and technical advice for DNA bank establishment and large scale genotyping. NMPH, OB, EWR obtained funding. NMPH, CS, OB, EWR are involved in SAPALDIA Cohort Study and UAL was the co-principal investigator of the SAPALDIA Cohort Study. SHD, CS, MI, OS did the health data management. MI, NMPH, SHD performed data analysis. SHD, CS gave statistical support. All authors contributed to the interpretation of the data and gave critical review during manuscript process. MI and NP drafted the manuscript and all authors read and approved the final manuscript.
###end p 103
###begin title 104
Acknowledgements
###end title 104
###begin p 105
###xml 22 34 <span type="species:ncbi:9606">participants</span>
The authors thank the participants of the SAPALDIA cohort for participation and interest in this research. We also thank Esther Glaus for her technical thoroughness in extracting the DNA.
###end p 105
###begin p 106
The SAPALDIA cohort study directorate is composed of principal investigator T. Rochat, the former co-principal investigator P. Leuenberger, U. Ackermann-Liebrich, J.C. Barthelemy, S.Liu, C. Schindler and NM. Probst-Hensch and of the numerous contributors of the SAPALDIA cohort study are not listed as authors: the local centre teams and coordinators of both SAPALDIA surveys and the members of the scientific SAPALDIA team: J.C. Barthelemy, R. Bettschart, A. Bircher, K. Blaser, G. Bolognini, M. Brutsche, L. Burdet, M. Frey, J.M. Gaspoz, M. Gerbase, D. Gold, W. Karrer, R. Keller, B. Knopfli, N. Kunzli, A. Morabia, U. Neu, L. Nicod, A.P. Perruchoud, M. Pons, T. Rochat, P. Schmid-Grendelmeyer, J. Schwartz, F. Schwarz, P. Straehl, J.M. Tschopp, A. von Eckardstein, J.P. Zellweger, E. Zemp Stutz, L. Bayer-Oglesby, D. Felber Dietrich, D. Keidel, B. Kuna-Dibbert, P. Stadele-Kessler.
###end p 106
###begin p 107
Funding Resources:
###end p 107
###begin p 108
The research has been supported by the Swiss National Science Foundation (grant Ndegrees 33-47CO-108796/1, Ndegrees NF32-65896.01, NF32-58996.99, NF32-54996.98 Prosper: NM. Probst), Freiwillige Akademische Gesellschaft Basel and Lung Ligue Zurich.
###end p 108
###begin article-title 109
The global burden of disease, 1990-2020
###end article-title 109
###begin article-title 110
Chronic obstructive pulmonary disease
###end article-title 110
###begin article-title 111
Clinically "small" effects of air pollution on FVC have a large public health impact. Swiss Study on Air Pollution and Lung Disease in Adults (SAPALDIA) - team
###end article-title 111
###begin article-title 112
Biological dust exposure in the workplace is a risk factor for chronic obstructive pulmonary disease
###end article-title 112
###begin article-title 113
###xml 92 97 <span type="species:ncbi:9606">women</span>
Long-term air pollution exposure and living close to busy roads are associated with COPD in women
###end article-title 113
###begin article-title 114
Directly measured secondhand smoke exposure and COPD health outcomes
###end article-title 114
###begin article-title 115
Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk
###end article-title 115
###begin article-title 116
The SERPINE2 Gene Is Associated with Chronic Obstructive Pulmonary Disease
###end article-title 116
###begin article-title 117
A functional mutation in the terminal exon of elastin in severe, early-onset chronic obstructive pulmonary disease
###end article-title 117
###begin article-title 118
Association of lung function decline with the heme oxygenase-1 gene promoter microsatellite polymorphism in a general population sample. Results from the European Community Respiratory Health Survey (ECRHS), France
###end article-title 118
###begin article-title 119
Genetic association analysis of functional impairment in chronic obstructive pulmonary disease
###end article-title 119
###begin article-title 120
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Evaluation of the toll-like receptor 6 Ser249Pro polymorphism in patients with asthma, atopic dermatitis and chronic obstructive pulmonary disease
###end article-title 120
###begin article-title 121
Genetic polymorphism of epoxide hydrolase and glutathione S-transferase in COPD
###end article-title 121
###begin article-title 122
The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance
###end article-title 122
###begin article-title 123
Glutathione S-transferase polymorphisms and their biological consequences
###end article-title 123
###begin article-title 124
###xml 129 137 <span type="species:ncbi:9606">children</span>
Genetic polymorphism of GSTM1 and antioxidant supplementation influence lung function in relation to ozone exposure in asthmatic children in Mexico City
###end article-title 124
###begin article-title 125
###xml 78 86 <span type="species:ncbi:9606">patients</span>
Protective role of glutathione S-transferase P1 (GSTP1) Val105Val genotype in patients with bronchial asthma
###end article-title 125
###begin article-title 126
###xml 90 98 <span type="species:ncbi:9606">children</span>
Glutathione-S-transferase M1, M3, P1 and T1 polymorphisms and severity of lung disease in children with cystic fibrosis
###end article-title 126
###begin article-title 127
Antioxidant gene polymorphisms and susceptibility to a rapid decline in lung function in smokers
###end article-title 127
###begin article-title 128
Effects of glutathione-S-transferase M1, T1, and P1 on childhood lung function growth
###end article-title 128
###begin article-title 129
###xml 137 149 <span type="species:ncbi:9606">participants</span>
Follow-up of the Swiss Cohort Study on Air Pollution and Lung Diseases in Adults (SAPALDIA 2) 1991-2003: methods and characterization of participants
###end article-title 129
###begin article-title 130
SAPALDIA: methods and participation in the cross-sectional part of the Swiss Study on Air Pollution and Lung Diseases in Adults
###end article-title 130
###begin article-title 131
Longitudinal validity of spirometers - a challenge in lung function follow-up studies
###end article-title 131
###begin article-title 132
Standardization of Spirometry, 1994 Update. American Thoracic Society
###end article-title 132
###begin article-title 133
Arlequin ver 2000: A software for population genetics data analysis.
###end article-title 133
###begin article-title 134
Analysis of data from multiclinic trials
###end article-title 134
###begin article-title 135
The glutathione S-transferase-mu and -theta genotypes in the etiology of prostate cancer: genotype-environment interactions with smoking
###end article-title 135
###begin article-title 136
Polymorphism at the glutathione S-transferase GSTP1 locus. A new marker for bronchial hyperresponsiveness and asthma
###end article-title 136
###begin article-title 137
Bronchial hyperresponsiveness and the development of asthma and COPD in asymptomatic individuals: SAPALDIA cohort study
###end article-title 137
###begin article-title 138
Physiological changes in respiratory function associated with ageing
###end article-title 138
###begin article-title 139
Glutathione S transferase deficiency and passive smoking increase childhood asthma
###end article-title 139
###begin article-title 140
Vitamin A, cigarette smoking, and airway obstruction
###end article-title 140
###begin article-title 141
Dietary antioxidant vitamin intake and lung function in the general population
###end article-title 141
###begin article-title 142
Antioxidant intake, GSTM1 polymorphism and pulmonary function in healthy young adults
###end article-title 142
###begin article-title 143
Air pollution and the elderly: oxidant/antioxidant issues worth consideration
###end article-title 143
###begin article-title 144
The value of forced expiratory volume in 1 second decline in the assessment of chronic obstructive pulmonary disease progression
###end article-title 144
###begin article-title 145
Pathologic changes in the peripheral airways of young cigarette smokers
###end article-title 145
###begin article-title 146
###xml 53 61 <span type="species:ncbi:9606">children</span>
Antioxidant supplementation and lung functions among children with asthma exposed to high levels of air pollutants
###end article-title 146
###begin article-title 147
Exposure to air pollution and pulmonary function in university students
###end article-title 147
###begin article-title 148
Genome-wide linkage of forced mid-expiratory flow in chronic obstructive pulmonary disease
###end article-title 148
###begin article-title 149
###xml 48 53 <span type="species:ncbi:9606">human</span>
Gender differences in airway behaviour over the human life span
###end article-title 149
###begin article-title 150
Predictors of loss of lung function in the elderly: the Cardiovascular Health Study
###end article-title 150
###begin article-title 151
###xml 71 74 <span type="species:ncbi:9606">men</span>
###xml 79 84 <span type="species:ncbi:9606">women</span>
Heterogeneity in effects from smoking on lung function decline between men and women - SAPALDIA 2 cohort study
###end article-title 151
###begin article-title 152
###xml 33 38 <span type="species:ncbi:9606">women</span>
###xml 49 52 <span type="species:ncbi:9606">men</span>
Changes in smoking status affect women more than men: results of the Lung Health Study
###end article-title 152
###begin article-title 153
Increased susceptibility to lung dysfunction in female smokers
###end article-title 153
###begin article-title 154
###xml 89 97 <span type="species:ncbi:9606">patients</span>
Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients
###end article-title 154
###begin article-title 155
###xml 72 79 <span type="species:ncbi:4097">tobacco</span>
Sex-related differences in bronchial epithelial changes associated with tobacco smoking
###end article-title 155
###begin article-title 156
Variable effects of exercise intensity on reduced glutathione, thiobarbituric acid reactive substance levels, and glucose concentration
###end article-title 156
###begin article-title 157
Plasma glutathione peroxidase in healthy young adults: influence of gender and physical activity
###end article-title 157
###begin article-title 158
###xml 67 72 <span type="species:ncbi:9606">human</span>
Age and sex influence on oxidative damage and functional status in human skeletal muscle
###end article-title 158
###begin article-title 159
Total antioxidant levels, gender, and age as risk factors for DNA damage in lymphocytes of the elderly
###end article-title 159
###begin article-title 160
Transcriptional regulation by the estrogen receptor of antioxidative stress enzymes and its functional implications
###end article-title 160
###begin article-title 161
Glutathione S-transferase variants and their interaction with smoking on lung function
###end article-title 161
###begin article-title 162
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Glutathione S-transferase P1 (GSTP1) polymorphism in patients with chronic obstructive pulmonary disease
###end article-title 162
###begin article-title 163
Lung function in healthy never smoking adults: reference values and lower limits of normal of a Swiss population
###end article-title 163
###begin article-title 164
Re-estimated equations for 5th percentiles of lung function variables
###end article-title 164
###begin article-title 165
###xml 38 43 <span type="species:ncbi:9606">women</span>
Increased fine particle deposition in women with asymptomatic nonspecific airway hyperresponsiveness
###end article-title 165
###begin article-title 166
Genetic susceptibility to chronic obstructive pulmonary disease in Koreans: combined analysis of polymorphic genotypes for microsomal epoxide hydrolase and glutathione S-transferase M1 and T1
###end article-title 166
###begin article-title 167
Glutathione-S-transferase family of enzymes
###end article-title 167
###begin article-title 168
Glutathione S-transferases and aromatic DNA adducts in smokers' bronchoalveolar macrophages
###end article-title 168
###begin article-title 169
###xml 60 64 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Increased constitutive c-Jun N-terminal kinase signaling in mice lacking glutathione S-transferase Pi
###end article-title 169
###begin article-title 170
###xml 63 68 <span type="species:ncbi:9606">human</span>
Depletion of glutathione S-transferase P1 induces apoptosis in human lung fibroblasts
###end article-title 170
###begin article-title 171
Population admixture: detection by Hardy-Weinberg test and its quantitative effects on linkage-disequilibrium methods for localizing genes underlying complex traits
###end article-title 171
###begin article-title 172
Use of unlinked genetic markers to detect population stratification in association studies
###end article-title 172
###begin article-title 173
Signature of recent historical events in the European Y-chromosomal STR haplotype distribution
###end article-title 173

